Seeking Alpha

An FDA panel votes unanimously against approval for Regeneron's (REGN -0.1%) Arcalyst, saying...

An FDA panel votes unanimously against approval for Regeneron's (REGN -0.1%) Arcalyst, saying it's unsafe for the treatment of gout flares. (transcript)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|